MedAlliance Acquired by Cordis in Landmark Deal, Expanding Access to Innovative Heart Disease Treatment
October 6, 2023 :MedAlliance, a pioneering Swiss medical device startup, has been acquired by Cordis, a Johnson & Johnson company, in a landmark USD 1.135 billion deal. The acquisition, announced on October 6, 2023, is expected to close in the first half of 2024.
Celltrion USA Expands Access to Yuflyma® Through Ventegra® Formulary Placement
October 6, 2023 : Celltrion USA, Inc., a leading biopharmaceutical company, today announced that it has signed a contract with Ventegra®, a major U.S. Medical Benefits Manager (MBM), to add Yuflyma® (adalimumab-aaty) as a preferred formulary product in both public and private insurance markets.
